Clinical Trials
394
Trial Phases
6 Phases
Drug Approvals
10
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (361 trials with phase data)• Click on a phase to view related trials
A Study of Oral E1018 in Healthy Adult Participants
- Conditions
- MalariaHealthy Participants
- Interventions
- Drug: E1018Drug: Placebo
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06854042
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population
- Conditions
- Sleep Initiation and Maintenance DisordersPregnancy
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 861
- Registration Number
- NCT06744673
- Locations
- 🇺🇸
Eisai Trial Site #1, Nutley, New Jersey, United States
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT06602258
- Locations
- 🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Bradenton Research Center, Bradenton, Florida, United States
A Study of E2086 in Healthy Adult Participants
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06481488
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
- Conditions
- Narcolepsy Type 1 (NT1)
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06462404
- Locations
- 🇺🇸
SDS Clinical Trials, Santa Ana, California, United States
🇺🇸PharmaDev Clinical Research, Miami, Florida, United States
🇺🇸Sleep Practioners, LLC, Macon, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 72
- Next
News
LEAP-001 Trial: Lenvatinib and Pembrolizumab Combination Fails to Improve Survival in Advanced Endometrial Cancer
The Phase III LEAP-001 trial evaluated lenvatinib plus pembrolizumab versus chemotherapy as a first-line treatment for advanced or recurrent endometrial cancer.
Lenvatinib Plus Ifosfamide/Etoposide Fails to Significantly Improve Progression-Free Survival in Relapsed Osteosarcoma
A phase II study (OLIE) found that adding lenvatinib to ifosfamide/etoposide did not significantly improve progression-free survival (PFS) in pediatric and young adult patients with relapsed osteosarcoma.